Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00
library@mnums.edu.mn
/

Han, Lai Fu

Loading...
Thumbnail Image
Товч нэр
Han, Lai Fu
Бүтэн нэр
Han Lai Fu
Латин нэр
Han Lai Fu
Албан тушаал
Судлаач
Харьяалал
ORCID

Settings

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Association between prostate cancer development and TARBP1
    (Mongolian National University of Medical Sciences, 2025-03-31)
    Wei Lui
    ;
    Bilegtsaikhan Tsolmon
    ;
    Ganbayar Batmunkh
    ;
    Lai Fu Han
    ;
    Shiirevnyamba Avirmed
    Objective: Prostate cancer is the most frequent cancer among elderly men worldwide and second cause of cancer-related deaths in man. Prostate cancer characterized a clinically heterogeneous and genetic alterations in cells play a pivotal role in carcinogenesis. A detailed understandings of the genetic alterations in cancer cells are important for developing new therapeutic medicine. Transactivation response RNA-binding protein1 (TARBP1) encodes a protein with RNA-binding, tRNA methyltransferase activity, and RNA interference regulation functions, but its association with prostate cancer remains unclear. The aim of this study was to investigate clinical significance of TARBP1 in prostate cancer. Methods: Relative messenger ribonucleic acid (mRNA) and protein expression of TARBP1 in prostate cancer cell and tumor tissue was determined by qRT-PCR and Western blot analysis. LNCaP cells with lentivirus vector to silence the expression of TARBP1 were injected into nude mice. After 24 days, the mice were killed and tumor tissues were excised. The size of tumors was measured using a ruler and body weight of mice were weighed using a scale. Results: Through qRT-PCR and Western blot analysis, we validated that the expression levels of TARBP1 was decreased in TARBP1-knockdown prostate cancer cell compared with cells transfected with negative control LV-shNC RNA. The tumor growths were significant smaller in the group B (LNCaP-LV-shTARBP1) compared with group A (LNCaP-LV-shNC). Knocking down TARBP1 significantly suppressed the tumor progression of BALB/C nude xenograft. Moreover, body weight of mice in LNCaP-LV-shNC group increased significant slowly compared with LNCaP-LV-shTARBP1 group. The result of western blot analysis for TARBP1 in tumor tissues from xenograft nude mice bearing orthotopic LNCaP tumors shows that the expression of TARBP1 was also significantly decreased in the LNCaP-LV-shTARBP1 group compared with LNCaP-LV-shNC group (p < 0.05). Conclusion: We revealed that the TARBP1 highly expressed in prostate cancer and its role in promoting tumor growth. TARBP1 could serve as a potential therapeutic target for prostate cancer treatment and it is also a biomarker for tumor diagnosis and prognosis.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Development of a risk model for bcr-free prognosis in prostate cancer patients linked to nucleotide metabolism
    (2025-03-03)
    Wei Liu
    ;
    Munkhtuya Tumurkhuu
    ;
    Naranjargal Davaadorj
    ;
    Tao Feng
    ;
    Ling Qin
    Introduction: Prostate cancer is a prevalent malignancy among elderly men, with bioinformatics playing a crucial role in advancing diagnosis and treatment paradigms. Recent studies have highlighted the significance of nucleotide metabolism (NM) in Prostate cancer development and progression, linking it to aggressive cancer phenotypes characterized by uncontrolled proliferation and metastasis. Understanding NM-related genes (NMRGs) could provide insights into Prostate cancer pathogenesis and therapeutic targets.Methods: This paper analyzed TCGA-PRAD and GSE70769 datasets to identify critical modules associated with NMRGs using weighted gene co-expression network analysis (WGCNA). Differentially expressed genes (DEGs) between Prostate cancer and control samples were extracted from the TCGA-PRAD dataset, with overlaps identified as NM-related DEGs (DE-NMRGs). A biochemical recurrence (BCR)-free risk model was constructed from 396 Prostate cancer samples, and patients were classified into high- and low-risk groups based on median risk scores. A nomogram model integrating key prognostic factors was developed to predict BCR rates.Results: This paper identified 5 prognostic genes: RGS11, KAT2A, MXD3, TARBP1, and WFIKKN. The low-risk group exhibited significantly higher BCR-free survival rates, ESTIMATE scores, and immunophenoscore (IPS) scores compared to the high-risk group. Additionally, potential therapeutic agents, including KU-55933 and Wee1 inhibitors, were proposed. Conclusions: The identified prognostic genes present promising targets for Prostate cancer diagnosis and treatment, emphasizing their importance in predicting biochemical recurrence and tailoring personalized therapeutic strategies for patients.